ReviewClinical and translational gastroenterology2026
Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges.
Review in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overcoming cancer resistance in pancreatic cancer: toward dynamic precision oncology.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer represents the most lethal malignancy among all gastrointestinal tumors. Recent medical advances, such as targeted therapy and immunotherapy, increasingly rely on tumor molecular profiling to tailor treatment of patients with advanced cancer. Given the risks associated with invasive biopsy, circulating cell-free DNA (cfDNA) has emerged as a cutting-edge approach for the detection and monitoring of cancer. The minimally invasive operation, coupled with the sensitive and timely detection of cancer across multiple clinical application, makes cfDNA a potential solution to transform precision oncology. Despite the advances, the expected widespread application of liquid-biopsy is still limited due to a series of substantial challenges in technique and clinical settings. In this article, we discuss technologies and methodologies in the detection of cfDNA. The opportunities to address substantial challenges, including achieving clinical meaningful detection sensitivities, enhancing of assay accessibility, evaluating the clinical sensitivity of circulating tumor DNA (ctDNA) burden in clinical settings, are highlighted to support the integration of liquid biopsies into cancer treatment. The most recent ctDNA-associated studies are summarized to provide a whole picture of the application of ctDNA in the adaptive management and surveillance of pancreatic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.